The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Eli Lilly's revenues will grow 1.1% and EPS will expand 14.1%.
The average estimate for revenue is $5.66 billion. On the bottom line, the average EPS estimate is $1.05.
Last quarter, Eli Lilly notched revenue of $5.96 billion. GAAP reported sales were 1.5% lower than the prior-year quarter's $6.05 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.85. GAAP EPS of $0.74 for Q4 were 3.9% lower than the prior-year quarter's $0.77 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 79.0%, 90 basis points better than the prior-year quarter. Operating margin was 21.3%, 90 basis points better than the prior-year quarter. Net margin was 13.9%, 30 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $22.95 billion. The average EPS estimate is $3.90.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 1,243 members out of 1,343 rating the stock outperform, and 100 members rating it underperform. Among 433 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 412 give Eli Lilly a green thumbs-up, and 21 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Eli Lilly is hold, with an average price target of $51.97.
Can your portfolio provide you with enough income to last through retirement? You'll need more than Eli Lilly. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
- Add Eli Lilly to My Watchlist.